MedTrace Logo

Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

NCT00716963 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-05-29

Study results available
· View outcomes & findings →

Summary

The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)

Conditions

  • Mild Intermittent Asthma

Interventions

DRUG

Fluticasone propionate (Flovent Diskus) 250 mcg

Flovent Diskus 250 mcg

DRUG

budesonide 400 mcg

budesonide 400 mcg

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Paul O'Byrne, MD · McMaster University

  • Gail Gauvreau, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716963 on ClinicalTrials.gov